Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Roche Diagnostics extends HCV immunoassay availability

Roche Diagnostics : 09 April, 2008  (New Product)
Roche Diagnostics’ Elecsys Anti-HCV (Hepatitis C Virus) assay has received regulatory approval in Europe for the E 170 analyser for Modular Analytics and the e 601 module for the cobas 6000 platform.
The Elecsys Anti-HCV Assay is already available on the Elecsys 2010 and the cobas e 411 instruments.

Hepatitis C virus (HCV) infection represents a major cause of death through the development of severe fibrosis, cirrhosis and liver cancer. The principal mode of transmission is parenteral exposure to infected blood or blood products that result from insufficient blood screening procedures mainly in developing countries, and contaminated needles or other invasive medical tools. Most people with hepatitis C became infected through blood transfusions received before 1992, the year when improved blood screening tests became available.

Acute Hepatitis C infection is often asymptomatic and many people are unaware that they are infected until they present with the complications of liver disease. Therefore elevated liver enzymes are often the first signs of chronic HCV infection. HCV antibody tests are used for the primary diagnosis of hepatitis C virus infection in patients with suspected liver disease.

'The addition of anti-HCV Assay to the E 170 analyzer for Modular Analytics and the e601 module for the cobas 6000 platform complements Roche's already comprehensive menu of hepatitis immunodiagnostic and liver function assays, all of which can be accurately and simultaneously measured on a single blood sample to identify the underlying liver disorder,' said Dirk Ehlers, head of Roche Professional Diagnostics. 'The addition of the E 170/cobas e 601 application for Anti-HCV is another important step in demonstrating Roche's commitment to addressing our customers needs in terms of laboratory efficiency and convenience.'

The Elecsys Anti-HCV test will be available internationally upon approval of the local regulatory agencies.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo